INOVIQ and Promega Sign Global Supply and Distribution Agreement for EXO-NET®

Madison, WI USA. — Promega and INOVIQ Ltd (ASX:IIQ) (INOVIQ) are collaborating to unlock the commercial potential of exosomes as a key biomarker in cancer research. This agreement will offer Promega customers world-class exosome solutions for manual, automated and high-throughput exosome isolation and nucleic acid extraction.

The strategic Supply and Distribution Agreement will provide researchers with world-class exosome research solutions to enable exosome biomarker discovery. This agreement will leverage INOVIQ’s EXO-NET® pan-exosome capture tool1 and Promega expertise in nucleic acid purification systems.

Building upon last year’s successful Co-Marketing Agreement (ASX: July 6, 2023), this agreement extends the commercial relationship between INOVIQ and Promega. The agreement is applicable worldwide, allowing researchers and industry easy global access to exosome research tools and solutions.

David Williams, Chairman of INOVIQ, said: “This partnership is a significant building block for commercialising our exosome technology platform and validates our focus on developing next generation exosome diagnostics and therapeutics. EXO-NET’s precision and efficiency, combined with Promega’s leading RNA extraction technologies, established reputation and global reach should drive transformative exosome research. This should yield development of exosome diagnostics from bench-to-clinic. In addition, I am impressed with Promega’s intended approach to marketing by leveraging AI to gain broader reach in presenting the benefits of scalable and efficient exosome isolation to researchers worldwide.”

Tom Livelli, Vice President Life Sciences at Promega, said: “Through our strong relationship with INOVIQ, we are advancing exosome research and enabling our global customers with the latest research and translational solutions. Together, we are setting new standards in the field, ensuring that researchers worldwide have the most effective tools at their disposal.”

INOVIQ has been collaborating with Promega to assess customer needs and develop, validate and promote exosome solutions for high-throughput exosome isolation and RNA extraction for biomarker discovery applications. The companies jointly developed the high-throughput EXO-NET system and successfully delivered several scientific posters, conference presentations and webinars that received excellent feedback.

1 Khanabdali et al., (2024) High-Throughput Surface Epitope Immunoaffinity Isolation of Extracellular Vesicles and Downstream Analysis. Biology Methods and Protocols.

About Promega Corporation

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors.


INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours. Learn more about INOVIQ and EXO-NET at and

< | >